Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | ALPG | P10696 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | AOC2 | O75106 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2865999 | 1.00 | GPR174 (0.40) | GPR174MAOBAOC3MEN1ALPL | |
| SCHEMBL2867777 | 0.79 | LSS (0.40) | L3MBTL1 | |
| SCHEMBL2867779 | 0.79 | LSS (0.40) | L3MBTL1 | |
| SCHEMBL2868632 | 0.77 | LSS (0.40) | GPR174AOC3ALOX15KCNA3L3MBTL1 | |
| SCHEMBL2868634 | 0.77 | LSS (0.40) | GPR174AOC3ALOX15KCNA3L3MBTL1 | |
| SCHEMBL1486040 | 0.74 | GPR174 (0.62) | GPR174MAOBAOC3MEN1ALPL | |
| SCHEMBL7428825 | 0.74 | KCNA3 (0.59) | KCNA3L3MBTL1 | |
| SCHEMBL2866504 | 0.74 | LMNA (0.39) | MAOBAOC3ALOX15AOC2MAOA | |
| SCHEMBL2866505 | 0.74 | LMNA (0.39) | MAOBAOC3ALOX15AOC2MAOA | |
| SCHEMBL1269879 | 0.73 | KMT2A (0.31) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728180-B2 | Method for producing ethers | KURARAY CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080262272-A1 | Method For Producing Ethers | KURARAY CO., LTD. (JP) | 2008-10-23 | — | — | US | disclosed |
| EP-1760061-A1 | METHOD FOR PRODUCING ETHERS | KURARAY CO., LTD. (JP) | 2007-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262272-A1 | Method For Producing Ethers | TELO2, PDS5A, TERT | GPR174 3363/4885MAOB 4049/4885AOC3 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.